Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of WCK 2349 in Healthy Adults
NCT02253342Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alalevonadifloxacin in bacterial pneumonia and acute bacterial skin and skin structure infections (ABSSSI), sponsored by Wockhardt. Primary endpoint: Concentrations of levonadifloxacin in Epithelial lining fluid (ELF) and alveolar macrophage (AM) at 5 days. Started Sep 2014; status: completed.
02
Drugs
alalevonadifloxacin
03
Conditions
bacterial pneumoniaacute bacterial skin and skin structure infections (ABSSSI)
Beyond the preview
Go deeper on NCT02253342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253342.